Previous 10 | Next 10 |
Worldwide revenue of $54.0 million – an increase of 14.8% year over year U.S. revenue of $43.0 million – an increase of 11.9% year over year International revenue of $11.0 million – an increase of 28.1% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a...
The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibr...
Exact Sciences (NASDAQ: EXAS ) added to Goldman Sachs Conviction List. More news on: Exact Sciences Corporation, AtriCure, Inc., Collegium Pharmaceutical, Inc., Healthcare stocks news, , Read more ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019. AtriCure will host a conference call ...
Intuitive Surgical (NASDAQ: ISRG ) initiated with Buy rating and $630 (9% upside) price target. Shares up a fraction premarket. More news on: Intuitive Surgical, Inc., AtriCure, Inc., Quest Diagnostics Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Needham & Company’s 18 th Annual Healthcare Conference in New York on Wednesday, April 10...
AtriCure Inc. (ATRC) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Lynn Lewis – Investor Relations Mike Carrel – President and Chief Executive Officer Andy Wade – Senior Vice President and Chief Financial Officer Confer...
AtriCure (NASDAQ: ATRC ) Q4 results ($M): Revenues: 52.9 (+14.8%); U.S.: 43.1 (+19.1%). More news on: AtriCure, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
AtriCure (NASDAQ: ATRC ): Q4 Non-GAAP EPS of -$0.21 misses by $0.04 ; GAAP EPS of -$0.09 beats by $0.08 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
2018 Worldwide revenue of $201.6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162.1 million – an increase of 17.2% year over year 2018 International revenue of $39.5 million – an increase of 8.7% year over year Atri...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...